Total Payments
$19,059
2024 Payments
$47.81
Companies
5
Transactions
16
Medicare Patients
13,423
Medicare Billing
$17.4M
Payment Breakdown by Category
Consulting$15,047 (78.9%)
Travel$1,825 (9.6%)
Other$1,750 (9.2%)
Food & Beverage$436.82 (2.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $15,047 | 4 | 78.9% |
| Travel and Lodging | $1,825 | 5 | 9.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,750 | 1 | 9.2% |
| Food and Beverage | $436.82 | 6 | 2.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech USA, Inc. | $16,983 | 11 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $1,829 | 2 | $0 (2019) |
| Heidelberg Engineering, Inc. | $176.88 | 1 | $0 (2017) |
| Apellis Pharmaceuticals, Inc. | $47.81 | 1 | $0 (2024) |
| Genentech, Inc. | $22.32 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $47.81 | 1 | Apellis Pharmaceuticals, Inc. ($47.81) |
| 2022 | $8,893 | 6 | Genentech USA, Inc. ($8,893) |
| 2020 | $1,815 | 1 | Genentech USA, Inc. ($1,815) |
| 2019 | $1,829 | 2 | Novartis Pharmaceuticals Corporation ($1,829) |
| 2018 | $6,297 | 5 | Genentech USA, Inc. ($6,275) |
| 2017 | $176.88 | 1 | Heidelberg Engineering, Inc. ($176.88) |
All Payment Transactions
16 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 01/05/2024 | Apellis Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $47.81 | General |
| 07/13/2022 | Genentech USA, Inc. | VABYSMO (Drug) | Food and Beverage | In-kind items and services | $101.25 | General |
| Category: Immunology and Ophthalmology | ||||||
| 07/12/2022 | Genentech USA, Inc. | VABYSMO (Drug) | Consulting Fee | Cash or cash equivalent | $5,880.00 | General |
| Category: Immunology and Ophthalmology | ||||||
| 07/12/2022 | Genentech USA, Inc. | VABYSMO (Drug) | Travel and Lodging | In-kind items and services | $384.53 | General |
| Category: Immunology and Ophthalmology | ||||||
| 07/12/2022 | Genentech USA, Inc. | VABYSMO (Drug) | Travel and Lodging | Cash or cash equivalent | $158.62 | General |
| Category: Immunology and Ophthalmology | ||||||
| 07/12/2022 | Genentech USA, Inc. | VABYSMO (Drug) | Travel and Lodging | Cash or cash equivalent | $16.38 | General |
| Category: Immunology and Ophthalmology | ||||||
| 02/25/2022 | Genentech USA, Inc. | Lucentis (Biological) | Consulting Fee | Cash or cash equivalent | $2,352.00 | General |
| Category: Ophthalmology | ||||||
| 10/24/2020 | Genentech USA, Inc. | Lucentis (Biological) | Consulting Fee | Cash or cash equivalent | $1,815.00 | General |
| Category: Ophthalmology | ||||||
| 10/10/2019 | Novartis Pharmaceuticals Corporation | BEOVU (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,750.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/10/2019 | Novartis Pharmaceuticals Corporation | BEOVU (Drug) | Food and Beverage | In-kind items and services | $79.37 | General |
| Category: OPHTHALMOLOGY | ||||||
| 09/15/2018 | Genentech, Inc. | Non-Covered Product (Drug) | Food and Beverage | In-kind items and services | $22.32 | General |
| Category: None | ||||||
| 09/12/2018 | Genentech USA, Inc. | Lucentis (Biological) | Consulting Fee | Cash or cash equivalent | $5,000.00 | General |
| Category: Ophthalmology | ||||||
| 09/12/2018 | Genentech USA, Inc. | Lucentis (Biological) | Travel and Lodging | In-kind items and services | $812.78 | General |
| Category: Ophthalmology | ||||||
| 09/12/2018 | Genentech USA, Inc. | Lucentis (Biological) | Travel and Lodging | In-kind items and services | $453.08 | General |
| Category: Ophthalmology | ||||||
| 09/12/2018 | Genentech USA, Inc. | Lucentis (Biological) | Food and Beverage | In-kind items and services | $9.19 | General |
| Category: Ophthalmology | ||||||
| 01/18/2017 | Heidelberg Engineering, Inc. | Spectralis (Device) | Food and Beverage | In-kind items and services | $176.88 | General |
| Category: Ophthalmology Imaging Equipment | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 23 | 2,987 | 21,101 | $19.0M | $4.5M |
| 2022 | 16 | 3,029 | 16,461 | $11.4M | $4.3M |
| 2021 | 21 | 3,329 | 17,257 | $7.1M | $4.1M |
| 2020 | 21 | 4,078 | 20,018 | $7.5M | $4.5M |
Total Patients
13,423
Total Services
74,837
Medicare Billing
$17.4M
Procedure Codes
81
All Medicare Procedures & Services
81 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 285 | 4,183 | $12.3M | $2.9M | 23.4% |
| Q5128 | Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | Office | 2023 | 122 | 2,312 | $1.3M | $500,704 | 38.7% |
| 67028 | Injection of drug into eye | Office | 2023 | 459 | 2,546 | $1.8M | $245,587 | 13.7% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2023 | 88 | 1,161 | $981,045 | $216,800 | 22.1% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2023 | 17 | 5,280 | $662,640 | $153,316 | 23.1% |
| 92134 | Imaging of retina | Office | 2023 | 824 | 3,217 | $527,588 | $96,478 | 18.3% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 586 | 934 | $470,736 | $85,756 | 18.2% |
| J3590 | Unclassified biologics | Office | 2023 | 38 | 194 | $230,720 | $66,578 | 28.9% |
| J3490 | Unclassified drugs | Office | 2023 | 18 | 34 | $151,300 | $60,128 | 39.7% |
| J2781 | Injection, pegcetacoplan, intravitreal, 1 mg | Office | 2023 | 16 | 330 | $98,010 | $39,719 | 40.5% |
| Q5124 | Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg | Office | 2023 | 16 | 200 | $88,600 | $34,809 | 39.3% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 112 | 114 | $53,694 | $12,628 | 23.5% |
| J9035 | Injection, bevacizumab, 10 mg | Office | 2023 | 76 | 231 | $57,750 | $12,523 | 21.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 98 | 98 | $63,798 | $11,963 | 18.8% |
| 67041 | Removal of membrane of retina | Facility | 2023 | 13 | 13 | $57,681 | $11,477 | 19.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 76 | 90 | $45,630 | $8,247 | 18.1% |
| 92012 | Established patient problem focused exam of visual system | Office | 2023 | 53 | 61 | $21,716 | $4,145 | 19.1% |
| 67228 | Destruction of leaking blood vessels of retina using laser | Office | 2023 | 11 | 14 | $18,676 | $3,534 | 18.9% |
| 92004 | New patient complete exam of visual system | Office | 2023 | 28 | 28 | $16,744 | $3,217 | 19.2% |
| 76512 | 2d ultrasound scan of eye tissue and structures | Office | 2023 | 16 | 21 | $4,116 | $839.51 | 20.4% |
| 67515 | Injection of drug or substance into membrane covering eyeball | Office | 2023 | 11 | 13 | $2,587 | $531.31 | 20.5% |
| 92250 | Photography of the retina | Office | 2023 | 13 | 14 | $2,198 | $398.30 | 18.1% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 11 | 13 | $845.00 | $10.86 | 1.3% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 280 | 3,878 | $6.8M | $2.8M | 41.0% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2022 | 146 | 4,274 | $2.1M | $953,339 | 44.6% |
About Dr. Sundeep Dev, MD
Dr. Sundeep Dev, MD is a Ophthalmology healthcare provider based in Minneapolis, Minnesota. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/18/2005. The National Provider Identifier (NPI) number assigned to this provider is 1497744924.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sundeep Dev, MD has received a total of $19,059 in payments from pharmaceutical and medical device companies, with $47.81 received in 2024. These payments were reported across 16 transactions from 5 companies. The most common payment nature is "Consulting Fee" ($15,047).
As a Medicare-enrolled provider, Dev has provided services to 13,423 Medicare beneficiaries, totaling 74,837 services with total Medicare billing of $17.4M. Data is available for 4 years (2020–2023), covering 81 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Location Minneapolis, MN
- Active Since 10/18/2005
- Last Updated 11/05/2010
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1497744924
Products in Payments
- Lucentis (Biological) $10,442
- VABYSMO (Drug) $6,541
- BEOVU (Drug) $1,829
- Spectralis (Device) $176.88
- Non-Covered Product (Drug) $22.32
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Minneapolis
Edwin Ryan, Md, MD
Ophthalmology — Payments: $9.5M
Ophthalmology $9.5M
Dr. Andrew Harrison, M.d, M.D
Ophthalmology — Payments: $198,088
Ophthalmology $198,088
David Hardten, M.d, M.D
Ophthalmology — Payments: $161,310
Ophthalmology $161,310
Dr. Sandra Rocio Montezuma, M.d, M.D
Ophthalmology — Payments: $55,602
Ophthalmology $55,602
Robert Mittra, Md, MD
Ophthalmology — Payments: $17,494
Ophthalmology $17,494
Dr. Ali Mokhtarzadeh, M.d, M.D
Ophthalmology — Payments: $6,738
Ophthalmology $6,738